You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

BELUMOSUDIL MESYLATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for belumosudil mesylate and what is the scope of patent protection?

Belumosudil mesylate is the generic ingredient in one branded drug marketed by Kadmon Pharms Llc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Belumosudil mesylate has forty-seven patent family members in twenty-seven countries.

One supplier is listed for this compound.

Summary for BELUMOSUDIL MESYLATE
International Patents:47
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:BELUMOSUDIL MESYLATE at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for BELUMOSUDIL MESYLATE
Generic Entry Date for BELUMOSUDIL MESYLATE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for BELUMOSUDIL MESYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kadmon Pharms Llc REZUROCK belumosudil mesylate TABLET;ORAL 214783-001 Jul 16, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Kadmon Pharms Llc REZUROCK belumosudil mesylate TABLET;ORAL 214783-001 Jul 16, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Kadmon Pharms Llc REZUROCK belumosudil mesylate TABLET;ORAL 214783-001 Jul 16, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Kadmon Pharms Llc REZUROCK belumosudil mesylate TABLET;ORAL 214783-001 Jul 16, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Kadmon Pharms Llc REZUROCK belumosudil mesylate TABLET;ORAL 214783-001 Jul 16, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for BELUMOSUDIL MESYLATE

Country Patent Number Title Estimated Expiration
Singapore 155163 PHARMACOKINETICALLY IMPROVED COMPOUNDS ⤷  Try a Trial
Serbia 63503 INHIBITORI RHO KINAZE (RHO KINASE INHIBITORS) ⤷  Try a Trial
South Korea 20080081122 PHARMACOKINETICALLY IMPROVED COMPOUNDS ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2014055996 ⤷  Try a Trial
Japan 2019034949 RHOキナーゼ阻害剤 (RHO KINASE INHIBITOR) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.